2025-09-12 – Press Releases – www.prnewswire.com
Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more than one year First and only chemotherapy-free combination in the first line setting to show survival improvement of this magnitude in a…
